HK Stock Market Move | BAO PHARMA-B(02659) rose more than 6% in morning trading. The world's first synthetic biological recombinant ustekinumab BJ044 has been approved for clinical use.

BAO PHARMA-B (02659) rose more than 6% in the early trading session, rising by 5.11% to 20.56 Hong Kong dollars with a trading volume of 6.0433 million Hong Kong dollars as of the time of writing. On the news front, at the end of June, Baoji Pharmaceutical announced that its independently developed BJ044 injection (recombinant urokinase) clinical trial application has been officially approved by the National Medical Products Administration. BJ044 is the world's first recombinant urokinase product developed using synthetic biology technology. With the comprehensive advantages of purity, safety, consistency, and cost-effectiveness, BJ044 is expected to systematically replace existing urine-extracted products. It is worth noting that this product, in conjunction with the company's other recombinant proteinase KJ101, jointly verifies the company's technical platform of "recombinant replacement of traditional bio-chemical extraction", relying on CHO, yeast expression systems to continuously improve the replication ability of traditional extractive drugs, and to build a differentiated recombinant protein innovation pipeline, distinguishing from the industry's homogenization research and development route of monoclonal antibodies and ADCs.